J?rg Tubel

List of Publications by Year in Descending Order

63 papers	1,385 citations	15 h-index	36 g-index
71 ext. papers	1,980 ext. citations	4.9 avg, IF	4.44 L-index

#	Paper	IF	Citations
63	Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers. *Scientific Reports*, **2021**, 11, 6404	4.9	
62	Comparing the consistency of electrocardiogram interval measurements by resting ECG versus 12-lead Holter. *Annals of Noninvasive Electrocardiology*, **2021**, 26, e12851	1.5	2
61	A Phase 1 Study to Investigate the Effects of Cortexolone 17α-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity. *Clinical Pharmacology in Drug Development*, **2021**, 10, 572-581	2.3	
60	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. *New England Journal of Medicine*, **2021**, 385, 493-502	59.2	180
59	Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single-Center Open-Label, Randomized Crossover Studies in Healthy Japanese Volunteers. *Clinical Pharmacology in Drug Development*,	2.3	
58	Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. *European Heart Journal*, **2021**, 42, 178-188	9.5	57
57	Kinetics of anti-SARS-CoV-2 IgG antibody levels and potential influential factors in subjects with COVID-19: A 11-month follow-up study. *Diagnostic Microbiology and Infectious Disease*, **2021**, 101, 115537	2.9	1
56	Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs. *Therapeutic Innovation and Regulatory Science*, **2020**, 54, 184-194	1.2	
55	Time- and Race-Specific Haematological Reference Intervals for Healthy Volunteer Trials: A Retrospective Analysis of Pooled Data From Multiple Phase I Trials. *Frontiers in Pharmacology*, **2020**, 11, 314	5.6	11
54	The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges. *Frontiers in Pharmacology*, **2020**, 11, 580560	5.6	0
53	Effects of the Fluoroquinolones Moxifloxacin and Levofloxacin on the QT Subintervals: Sex Differences in Ventricular Repolarization. *Journal of Clinical Pharmacology*, **2020**, 60, 400-408	2.9	8
52	Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs. *Therapeutic Innovation and Regulatory Science*, **2019**, 216847901882108	1.2	
51	Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone. *British Journal of Clinical Pharmacology*, **2019**, 85, 1516-1527	3.8	3
50	Practical risk management in early phase clinical trials. *European Journal of Clinical Pharmacology*, **2019**, 75, 483-496	2.8	3
49	Diurnal Profile of the QTc Interval Following Moxifloxacin Administration. *Journal of Clinical Pharmacology*, **2019**, 59, 35-44	2.9	6
48	BMS-986278, a lysophosphatidic acid 1 (LPA1) receptor antagonist, in healthy participants: A single/multiple ascending dose (SAD/MAD) phase 1 study **2019**,		4
47	The Cardiovascular Effects of a Meal: J-T and T -T Assessment and Further Insights Into the Physiological Effects. *Journal of Clinical Pharmacology*, **2019**, 59, 799-810	2.9	5

46	Efficacy and Safety of MED2005, a Topical Glyceryl Trinitrate Formulation, in the Treatment of Erectile Dysfunction: A Randomized Crossover Study. *Journal of Sexual Medicine*, **2018**, 15, 167-175	1.1	7
45	Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2 receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women. *British Journal of Clinical Pharmacology*, **2018**, 84, 1839-1855	3.8	7
44	Confirmation of the Cardiac Safety of PGF Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments. *Clinical Pharmacology in Drug Development*, **2018**, 7, 889-900	2.3	9
43	Estimation of the Power of the Food Effect on QTc to Show Assay Sensitivity. *Journal of Clinical Pharmacology*, **2018**, 58, 81-88	2.9	6
42	Practical risk management for adaptive integrated early phase clinical trials. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO2-8-2	0	1
41	Cardiac Safety of Rupatadine in a Single-Ascending-Dose and Multiple-Ascending-Dose Study in Healthy Japanese Subjects, Using Intensive Electrocardiogram Assessments-Comparison With the Previous White Caucasian Thorough QT Study. *Clinical Pharmacology in Drug Development*, **2018**, 7, 67-76	2.3	6
40	The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development. *Frontiers in Pharmacology*, **2018**, 9, 1301	5.6	1
39	Stability of the Effect of a Standardized Meal on QTc. *Annals of Noninvasive Electrocardiology*, **2017**, 22,	1.5	6
38	Time of the Day and Magnitude of the Effect of a Drug on the QTc Interval. *CPT: Pharmacometrics and Systems Pharmacology*, **2017**, 6, 283	4.5	2
37	A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. *New England Journal of Medicine*, **2017**, 376, 41-51	59.2	397
36	Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. *British Journal of Clinical Pharmacology*, **2017**, 83, 339-348	3.8	28
35	Pharmacokinetics and Pharmacodynamics of Lomitapide in Japanese Subjects. *Journal of Atherosclerosis and Thrombosis*, **2016**, 23, 606-20	4	6
34	Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial. *PLoS ONE*, **2016**, 11, e0163020	3.7	9
33	Comparison of Digital 12-Lead ECG and Digital 12-Lead Holter ECG Recordings in Healthy Male Subjects: Results from a Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. *Annals of Noninvasive Electrocardiology*, **2016**, 21, 588-594	1.5	6
32	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. *Clinical and Translational Gastroenterology*, **2015**, 6, e94	4.2	79
31	The reproducibility of QTc changes after meal intake. *Journal of Electrocardiology*, **2015**, 48, 274-5	1.4	9
30	Single Doses up to 800 mg of E-52862 Do Not Prolong the QTc Interval--A Retrospective Validation by Pharmacokinetic-Pharmacodynamic Modelling of Electrocardiography Data Utilising the Effects of a Meal on QTc to Demonstrate ECG Assay Sensitivity. *PLoS ONE*, **2015**, 10, e0136369	3.7	11
29	The Power of Phase I Studies to Detect Clinical Relevant QTc Prolongation: A Resampling Simulation Study. *BioMed Research International*, **2015**, 2015, 293564	3	15

28	A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results. *Blood*, **2015**, 126, 2413-2413	2.2	11
27	Analyzing the relationship of QT interval and exposure to nitazoxanide, a prospective candidate for influenza antiviral therapy--A formal TQT study. *Journal of Clinical Pharmacology*, **2014**, 54, 987-94	2.9	6
26	Three steps to writing adaptive study protocols in the early phase clinical development of new medicines. *BMC Medical Research Methodology*, **2014**, 14, 84	4.7	14
25	Concentration-effect modeling based on change from baseline to assess the prolonging effect of drugs on QTc together with an estimate of the circadian time course. *Journal of Clinical Pharmacology*, **2014**, 54, 1400-6	2.9	15
24	Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. *British Journal of Clinical Pharmacology*, **2014**, 77, 170-9	3.8	35
23	Tolerability and pharmacokinetics of ACT-280778, a novel nondihydropyridine dual L/T-type calcium channel blocker: early clinical studies in healthy male subjects using adaptive designs. *Journal of Cardiovascular Pharmacology*, **2014**, 63, 120-31	3.1	4
22	A pan-European registration system for volunteer participation is within sight. *European Journal of Clinical Pharmacology*, **2013**, 69, 729	2.8	2
21	Insulin at normal physiological levels does not prolong QT(c) interval in thorough QT studies performed in healthy volunteers. *British Journal of Clinical Pharmacology*, **2013**, 75, 392-403	3.8	18
20	Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study. *PLoS ONE*, **2013**, 8, e58438	3.7	8
19	Mason-Likar electrode configuration can confound the recognition of electrode cable interchange. *Journal of Electrocardiology*, **2012**, 45, 265	1.4	
18	Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QT(c) interval in healthy volunteers. *British Journal of Clinical Pharmacology*, **2012**, 74, 296-303	3.8	4
17	Shortening of the QT interval after food can be used to demonstrate assay sensitivity in thorough QT studies. *Journal of Clinical Pharmacology*, **2012**, 52, 1558-65	2.9	50
16	The practical application of adaptive study design in early phase clinical trials: a retrospective analysis of time savings. *European Journal of Clinical Pharmacology*, **2012**, 68, 543-51	2.8	13
15	Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects (pages. *British Journal of Clinical Pharmacology*, **2012**, 73, 455-9	3.8	15
14	Comparison of six commonly used QT correction models and their parameter estimation methods. *Journal of Biopharmaceutical Statistics*, **2012**, 22, 1148-61	1.3	9
13	Bupivacaine extended release liposome injection does not prolong QTc interval in a thorough QT/QTc study in healthy volunteers. *Journal of Clinical Pharmacology*, **2012**, 52, 1441-7	2.9	33
12	Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers. *British Journal of Clinical Pharmacology*, **2010**, 69, 391-400	3.8	29
11	A nonparametric approach to QT interval correction for heart rate. *Journal of Biopharmaceutical Statistics*, **2010**, 20, 508-22	1.3	8

10	Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. *British Journal of Clinical Pharmacology*, **2008**, 66, 396-404	3.8	72
9	The suppression of gastro-oesophageal reflux by alginates. *International Journal of Clinical Practice*, **2007**, 61, 1654-62	2.9	12
8	Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers. *Clinical Drug Investigation*, **2006**, 26, 21-8	3.2	10
7	Comparison of Ethnic Difference in Pharmacological Parameter.. *Japanese Journal of Clinical Pharmacology and Therapeutics*, **2003**, 34, 207S-208S	0	
6	The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. *British Journal of Clinical Pharmacology*, **2002**, 53 Suppl 1, 37S-43S	3.8	39
5	A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH. *Alimentary Pharmacology and Therapeutics*, **2001**, 15, 1807-17	6.1	20
4	Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. *American Journal of Gastroenterology*, **2001**, 96, 2058-65	0.7	37
3	Burns after photodynamic therapy. *BMJ: British Medical Journal*, **2000**, 320, 1245		22
2	NG lansoprazole or IV pantoprazole: Which provides better pH control?. *Gastroenterology*, **2000**, 118, A659	13.3	2
1	Burns after photodynamic therapy. Drug point gives misleading impression of incidence of burns with temoporfin (Foscan). *BMJ: British Medical Journal*, **2000**, 320, 1731-2		10